Anti-psychotics
... o Atypical APDs (esp. ziprasidone): significant risk of QT prolongation o Overall: ~2x increased risk of sudden cardiac death with both typical and atypical (dose-dependent) Endocrine Effects: o Hyperprolactinemia: manifest as amenorrhea, galactorrhea, infertility, impotence ...
... o Atypical APDs (esp. ziprasidone): significant risk of QT prolongation o Overall: ~2x increased risk of sudden cardiac death with both typical and atypical (dose-dependent) Endocrine Effects: o Hyperprolactinemia: manifest as amenorrhea, galactorrhea, infertility, impotence ...
Slide 1
... Antipsychotic may cause acute dystonic reaction. As in (a), either antipsychotic or benzodiazepine may be used alone, but best results are likely with combination therapy. Ensure flumazenil injection is available to reverse effects of lorazepam injection. The maximum dose of olanzapine is 20mg/24 ho ...
... Antipsychotic may cause acute dystonic reaction. As in (a), either antipsychotic or benzodiazepine may be used alone, but best results are likely with combination therapy. Ensure flumazenil injection is available to reverse effects of lorazepam injection. The maximum dose of olanzapine is 20mg/24 ho ...
Pharm II - 2-22
... a. High potency typicals have a reduced risk of EPS b.Low potency typicals are less efficacious than higher potency antipsychotics c. Atypical antipsychotics have increased affinity for D2 as compared to typical antipsychotics d.Increased anticholinergic activity reduces the risk of EPS ...
... a. High potency typicals have a reduced risk of EPS b.Low potency typicals are less efficacious than higher potency antipsychotics c. Atypical antipsychotics have increased affinity for D2 as compared to typical antipsychotics d.Increased anticholinergic activity reduces the risk of EPS ...
What is mental life
... myocarditis and seizures at very high doses o Sedation, weight gain, orthostatic hypotension. o This is a GREAT drug but you must first fail two other drugs before you can be started on this because of serious side effect risks. ...
... myocarditis and seizures at very high doses o Sedation, weight gain, orthostatic hypotension. o This is a GREAT drug but you must first fail two other drugs before you can be started on this because of serious side effect risks. ...
Bipolar Disorder Discussion
... Bipolar Disorder - Definition • Types: – Bipolar I – Bipolar II – Mixed episodes – Rapid cycling 1y ...
... Bipolar Disorder - Definition • Types: – Bipolar I – Bipolar II – Mixed episodes – Rapid cycling 1y ...
NEUROLEPTICS
... Smoking: 3 times more likely in schizophrenia than general population Excessive mortality 20% shorter life expectancy 10% suicide rate ...
... Smoking: 3 times more likely in schizophrenia than general population Excessive mortality 20% shorter life expectancy 10% suicide rate ...
medical student anti.. - University of Illinois at Chicago
... “Lead-In” combinations - typicals supposedly having more rapid action during acute emergency) “Top-Up” combinations - addition of typical to overcome acute exacerbation ...
... “Lead-In” combinations - typicals supposedly having more rapid action during acute emergency) “Top-Up” combinations - addition of typical to overcome acute exacerbation ...
Click here for handout
... • Introduction: Purpose of the study was to test two dose ranges of risperidone vs. placebo in adolescents with schizophrenia. • Methods: An RTC of risperidone (1-3 mg/d) vs. risperidone (4-6 mg/d) vs. placebo over 6 weeks. • Results: One hundred sixty seven patients participated in the study which ...
... • Introduction: Purpose of the study was to test two dose ranges of risperidone vs. placebo in adolescents with schizophrenia. • Methods: An RTC of risperidone (1-3 mg/d) vs. risperidone (4-6 mg/d) vs. placebo over 6 weeks. • Results: One hundred sixty seven patients participated in the study which ...
Psychosis Dr T Rogers 2014
... RFR: brought to ER by police due to concern over bizarre behaviour (wearing a winter coat during the heat wave, wandering through traffic, talking/yelling to self). ...
... RFR: brought to ER by police due to concern over bizarre behaviour (wearing a winter coat during the heat wave, wandering through traffic, talking/yelling to self). ...
Blockade of D2 receptor increases prolactin release and causes
... lack of expression, decrease in speech patterns ...
... lack of expression, decrease in speech patterns ...
Biopsychosocial Model For Psychosis
... • Metabolised P450 2D6 with an active metabolite. Possible interactions with TCAs, SSRIs, phenothiazines, beta-blockers, quinidine • start 0.5mg and increase • care with orthostatic effects • Long acting injection not released in Australia • Recently shown to be more effective than typical antipsych ...
... • Metabolised P450 2D6 with an active metabolite. Possible interactions with TCAs, SSRIs, phenothiazines, beta-blockers, quinidine • start 0.5mg and increase • care with orthostatic effects • Long acting injection not released in Australia • Recently shown to be more effective than typical antipsych ...
Hypnotics and Sedatives
... • Blocks selective D2, norepinephrine, and 5-HT2 • effective for positive and negative symptoms • Extrapyramidal side effects low (but are shown at high doses) • Shares sedation, weight gain, rapid heart beat, orthostatic hypotension, and elevated prolactin ...
... • Blocks selective D2, norepinephrine, and 5-HT2 • effective for positive and negative symptoms • Extrapyramidal side effects low (but are shown at high doses) • Shares sedation, weight gain, rapid heart beat, orthostatic hypotension, and elevated prolactin ...
Joanna Moncrieff
... • I’ve never been able to eat as much as I did when I was on Zyprexa. I gained 40lbs in no time and my mind was in a constant fog of lethargy and indifference. I didn’t care about anything. I just wanted to sit around and eat. ...
... • I’ve never been able to eat as much as I did when I was on Zyprexa. I gained 40lbs in no time and my mind was in a constant fog of lethargy and indifference. I didn’t care about anything. I just wanted to sit around and eat. ...
Slide 1
... of extrapyramidal side effects and tardive dyskinesia, but acknowledges debate over the relative advantages, disadvantages, and cost-effectiveness of first- and secondgeneration agents. The guideline also states that for some patients, a first-generation agent may be an appropriate first-line option ...
... of extrapyramidal side effects and tardive dyskinesia, but acknowledges debate over the relative advantages, disadvantages, and cost-effectiveness of first- and secondgeneration agents. The guideline also states that for some patients, a first-generation agent may be an appropriate first-line option ...
The Treatment of Psychotic Disorders
... Problems with Typical Antipsychotics • Solves no negative symptoms • EPS are very troublesome • Glutamatergic vs. Dopaminergic ...
... Problems with Typical Antipsychotics • Solves no negative symptoms • EPS are very troublesome • Glutamatergic vs. Dopaminergic ...
PSYCHOSIS IN CHILDHOOD AND ADOLESCENCE
... N.B. Will often not volunteer psychotic symptoms. Thought Disorder “Trouble with thinking clearly” Hallucinations “Strange experiences recently, hearing voices when no one there, people talking about you” Delusions “unusual events recently monitored in any way, strange experiences watching T ...
... N.B. Will often not volunteer psychotic symptoms. Thought Disorder “Trouble with thinking clearly” Hallucinations “Strange experiences recently, hearing voices when no one there, people talking about you” Delusions “unusual events recently monitored in any way, strange experiences watching T ...
This newsletter is for your information only and is not a substitute for
... effect. The primary risk is from long term (usually years, rarely, if ever, less than six months), high dose treatment with the older typical antipsychotics which are also known as neuroleptics. The risk of TD is close to none for low dose short term (weeks to months) use. The risk of TD with the ol ...
... effect. The primary risk is from long term (usually years, rarely, if ever, less than six months), high dose treatment with the older typical antipsychotics which are also known as neuroleptics. The risk of TD is close to none for low dose short term (weeks to months) use. The risk of TD with the ol ...
Antipsychotic Use in Pregnancy 2013
... There is limited data in the literature to address the use of antipsychotic medications in pregnant women. To aid practitioners, this guide was created by evaluating the available literature and it will assist practitioners as they provide treatment options and assist women to make the best decision ...
... There is limited data in the literature to address the use of antipsychotic medications in pregnant women. To aid practitioners, this guide was created by evaluating the available literature and it will assist practitioners as they provide treatment options and assist women to make the best decision ...
Initial Dosing and Clinical Titration of Antipsychotic Drugs in
... Clinical trials conducted by the manufacturers identified dose ranges for the atypical agents which produce, on average, good clinical efficacy with reduced extrapyramidal side effects (Table). However, the optimal dose for several agents for some clinical indications remains uncertain. Higher doses ...
... Clinical trials conducted by the manufacturers identified dose ranges for the atypical agents which produce, on average, good clinical efficacy with reduced extrapyramidal side effects (Table). However, the optimal dose for several agents for some clinical indications remains uncertain. Higher doses ...
Natural History of Schizophrenia
... Superior efficacy for positive symptoms Possible advantages for negative symptoms Virtually no EPS or TD Advantages in reducing hostility, suicidality Associated with agranulocytosis (1-2%) – WBC count monitoring required ...
... Superior efficacy for positive symptoms Possible advantages for negative symptoms Virtually no EPS or TD Advantages in reducing hostility, suicidality Associated with agranulocytosis (1-2%) – WBC count monitoring required ...
THERAPY WITH OLANZAPINE ORALLY DISINTEGRATING
... of 15 mg, and weight loss was similar (14 kg vs. 15 kg). In the second case report, the patient started working two weeks after baseline. The patients did not have any other changes regarding treatment, or generally in their behavior regarding health habits and life stile. Obesity related weight gai ...
... of 15 mg, and weight loss was similar (14 kg vs. 15 kg). In the second case report, the patient started working two weeks after baseline. The patients did not have any other changes regarding treatment, or generally in their behavior regarding health habits and life stile. Obesity related weight gai ...
Petra Jurina
... bi- means two; pol/o means extreme - brain disorder that causes unusual shifts in a person’s moods, energy and ability to function - symptoms are severe - cycles last days, weeks, months - first manic or depressive episode usually in adolescence ...
... bi- means two; pol/o means extreme - brain disorder that causes unusual shifts in a person’s moods, energy and ability to function - symptoms are severe - cycles last days, weeks, months - first manic or depressive episode usually in adolescence ...
Practice Debate
... and warnings of a possible increased mortality risk are mentioned in the New Zealand product information for risperidone and olanzapine. The FDA report indicated a class effect so this warning should also apply to quetiapine which appears to be widely used for BPSD although not approved (as per drug ...
... and warnings of a possible increased mortality risk are mentioned in the New Zealand product information for risperidone and olanzapine. The FDA report indicated a class effect so this warning should also apply to quetiapine which appears to be widely used for BPSD although not approved (as per drug ...
Olanzapine
Olanzapine (originally branded Zyprexa) is an atypical antipsychotic. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder.Olanzapine is structurally similar to clozapine and quetiapine, but is classified as a thienobenzodiazepine. The olanzapine formulations are manufactured and marketed by the pharmaceutical company Eli Lilly and Company; the drug went generic in 2011. Sales of Zyprexa in 2008 were $2.2B in the US, and $4.7B worldwide.